Holen Sie sich die Stockscreener-App
21.07
1.84%
0.38
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BAX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$20.69
Offen:
$20.9
24-Stunden-Volumen:
11.37M
Relative Volume:
1.41
Marktkapitalisierung:
$10.83B
Einnahmen:
$10.89B
Nettoeinkommen (Verlust:
$-241.00M
KGV:
-79.33
EPS:
-0.2656
Netto-Cashflow:
$340.00M
1W Leistung:
+8.05%
1M Leistung:
+16.02%
6M Leistung:
-29.32%
1J Leistung:
-28.79%
1-Tages-Spanne:
$20.61
$21.25
1-Wochen-Bereich:
$19.54
$21.25
52-Wochen-Spanne:
$17.40
$37.74
Baxter International Inc Stock (BAX) Company Profile
Firmenname
Baxter International Inc
Sektor
Telefon
(224) 948-2000
Adresse
ONE BAXTER PARKWAY, DEERFIELD, IL
Vergleichen Sie BAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
21.07 | 10.64B | 10.89B | -241.00M | 340.00M | -0.2656 |
|
ISRG
Intuitive Surgical Inc
|
586.24 | 207.41B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
202.75 | 58.46B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.13 | 39.60B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
252.47 | 36.63B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
MDLN
Medline Inc
|
40.52 | 32.47B | 27.43B | 1.27B | 1.01B | 1.5829 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Herabstufung | Argus | Buy → Hold |
| 2025-08-04 | Herabstufung | Stifel | Buy → Hold |
| 2025-08-01 | Herabstufung | Goldman | Buy → Neutral |
| 2025-02-26 | Fortgesetzt | Goldman | Buy |
| 2025-02-24 | Hochstufung | Argus | Hold → Buy |
| 2025-02-20 | Fortgesetzt | Barclays | Overweight |
| 2024-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-12-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-06-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-18 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-18 | Bestätigt | Raymond James | Outperform |
| 2022-02-18 | Bestätigt | Stifel | Buy |
| 2022-02-18 | Bestätigt | UBS | Neutral |
| 2022-02-18 | Bestätigt | Wells Fargo | Overweight |
| 2022-02-11 | Eingeleitet | Goldman | Neutral |
| 2022-01-07 | Fortgesetzt | Citigroup | Buy |
| 2022-01-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-09-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | Herabstufung | UBS | Buy → Neutral |
| 2020-12-15 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-09-04 | Herabstufung | Argus | Buy → Hold |
| 2020-06-24 | Eingeleitet | Oppenheimer | Outperform |
| 2020-03-19 | Hochstufung | Stifel | Hold → Buy |
| 2020-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-01-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-01-02 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | Hochstufung | Argus | Hold → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-05-17 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-06 | Bestätigt | Citigroup | Neutral |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
Alle ansehen
Baxter International Inc Aktie (BAX) Neueste Nachrichten
The Truth About Baxter International Inc.: Why Wall Street Suddenly Can’t Ignore It - AD HOC NEWS
Barclays Adjusts Price Target on Baxter International to $30 From $36, Maintains Overweight Rating - MarketScreener
Baxter International Inc.: How a 90-Year Medtech Veteran Is Rebuilding Its Flagship Portfolio - AD HOC NEWS
Why Baxter International Inc. stock is in analyst buy zoneJuly 2025 Reactions & Community Trade Idea Sharing Platform - ulpravda.ru
Is Baxter International Inc. stock affected by interest rate hikesJuly 2025 Price Swings & Safe Capital Investment Plans - ulpravda.ru
Breakout Move: Can Baxter International Inc. stock attract ESG capital inflowsJuly 2025 Chart Watch & Technical Pattern Recognition Alerts - ulpravda.ru
Will Baxter International Inc. stock outperform Nasdaq index2025 Major Catalysts & AI Optimized Trading Strategy Guides - ulpravda.ru
How strong is Baxter International Inc. stock revenue growthJuly 2025 WrapUp & AI Driven Price Predictions - ulpravda.ru
MUSC Health and Baxter partner to enhance patient care with technology - Investing.com Australia
Is Baxter International Inc. stock vulnerable to regulatory risksExit Point & Fast Moving Market Watchlists - ulpravda.ru
MUSC Health and Baxter Announce Strategic Partnership to Transform Bedside Care Delivery and Address - PharmiWeb.com
Baxter partnership - The Medical University of South Carolina
Signal Recap: Can Baxter International Inc. stock weather global recession2025 Price Targets & High Win Rate Trade Alerts - ulpravda.ru
Will Baxter International Inc. stock see insider accumulationTrade Entry Summary & High Return Trade Guides - ulpravda.ru
MUSC Health and Baxter Announce Strategic Partnership to Transform Bedside Care Delivery and Address Critical Nursing Challenges - Business Wire
Fund Update: 4,404,874 BAXTER INTERNATIONAL (BAX) shares added to GREENHAVEN ASSOCIATES INC portfolio - Quiver Quantitative
Baxter to Present at J.P. Morgan 2026 Healthcare Conference - MarketScreener
How to watch Baxter’s CEO at the 2026 J.P. Morgan healthcare conference - Stock Titan
New fraud claims filed in federal lawsuits against IV pump company - KMOV
Baxter International (NYSE:BAX) Given New $23.00 Price Target at Evercore ISI - MarketBeat
The Truth About Baxter International (NYSEreplacing with BCRX): Is This Biotech Underdog About To - AD HOC NEWS
Evercore ISI Adjusts Price Target on Baxter International to $23 From $24 - MarketScreener
BofA Securities Maintains Baxter International Inc(BAX.US) With Hold Rating, Cuts Target Price to $24 - 富途牛牛
Artisan Mid Cap Value Fund’s Views on Baxter International (BAX) - Insider Monkey
How Investors Are Reacting To Baxter (BAX) Debt Tender Offers And Smart Infusion EMR Data - simplywall.st
Assessing Baxter International (BAX) Valuation After Recent Share Price Momentum And Margin Concerns - Yahoo Finance
How Investors May Respond To Baxter (BAX) Retiring Near‑Term Debt And Advancing Connected Infusion Therapy - Yahoo Finance
The Truth About Baxter International Inc.: Is This ‘Boring’ Stock a Secret Power Play? - AD HOC NEWS
Baxter International (BAX) and Vaneck Gold Miners ETF (GDX) top the Bull Strangle watch list for next week - Barchart.com
Baxter International Inc Stock Price Live, Charts & News - The Economic Times
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
What do analysts think about Baxter International Inc. (BAX)? - MSN
What Do Analysts Think About Baxter International Inc. (BAX)? - Insider Monkey
Who Owns Baxter International? Top Shareholders and Recent Insider Trades - TIKR.com
IV Bags Market to See Massive Growth with Baxter, B. Braun, Fresenius Kabi, and Terumo - openPR.com
Opportunities and Competition in the $1.19 Billion U.S. IV - GlobeNewswire
Opportunities and Competition in the $1.19 Billion U.S. IV Bags Market, 2025-2033, Featuring Baxter International, Kraton, Technoflex, B. Braun Medical, Sippex IV Bags and More - Yahoo Finance
Baxter International Inc. (NYSE:BAX) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Here's Why Baxter International (NYSE:BAX) Has A Meaningful Debt Burden - 富途牛牛
Baxter International (BAX) in 2025: A Deep Dive into the Transformation of a MedTech Giant - FinancialContent
Reasons to Retain Baxter International Stock in Your Portfolio Now - TradingView — Track All Markets
Insider Sell: Will Baxter International Inc stock outperform international peersWeekly Trade Report & Weekly Stock Performance Updates - moha.gov.vn
Baxter International Sees Unusually High Options Volume (NYSE:BAX) - MarketBeat
How Investors Are Reacting To Baxter International (BAX) Novum LVP Infusion Pump Class Action Allegations - Sahm
Baxter International (BAX) Concludes Tender Offers with Final Se - GuruFocus
Baxter International completes final settlement of tender offers for senior notes - Investing.com India
Baxter International completes final settlement of tender offers for senior notes By Investing.com - Investing.com South Africa
Baxter International Completes Cash Tender Offers, Cuts Debt - TipRanks
Baxter International Finalizes Tender Offers Settlement - TradingView — Track All Markets
Baxter International Inc. Effects the Final Settlement of the Company?s Previously Announced Cash Tender Offers - marketscreener.com
Argus Research Downgrades Baxter International Inc. (BAX)’s Rating To Hold Following Dividend Cut - MSN
Finanzdaten der Baxter International Inc-Aktie (BAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.30%
0.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):